Gilead Sciences Receives Subpoena from U.S. Department of Health & Human Services Regarding Ranexa(R)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 14, 2009-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services requesting documents regarding the development, marketing and sales of Ranexa ® (ranolazine). Ranexa is approved for the treatment of chronic angina and was developed and originally commercialized by CV Therapeutics, a company that Gilead acquired in April 2009 . About Gilead Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California , Gilead has operations in North America , Europe and Australia . For more information on Gilead Sciences , please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). Source: Gilead Sciences, Inc. Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Amy Flood, 650-522-5643 (Media)

The release as fetched from its publisher. gilead.com ↗